Aseptic Process Validation

Similar documents
VALIDATION OF ASEPTIC PROCESSES

Media Fill A Process Simution. Presented By Shikha Chauhan

Review Validation of aseptic processes for pharmaceuticals

ANNEX 1: COMMENT SUBMISSION DOCUMENT

FDA s Guidance for Industry

Overview and Introduction Annex 1 Revision

Overview of a sterility assurance program for PET drugs

Aseptic Processing Practices and Process Validation of Aseptic Operators

September 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Overview of Inspection Issues with Legacy Products

HVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

For sterile products manufacturing, Lyoseal is an innovative technology. presented by Mr. Tony Bouzerar from BioCorp offers us detailed

SITE MASTER FILE For MHRA

Points to Consider for Aseptic Processing Part 2 May 2016

Complaints Investigations Root Cause Analysis

Environmental Monitoring of Aseptic Processing Areas - 1

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

INSPECTION OF BIOTECHNOLOGY MANUFACTURES

Overview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer

Annex 1 to the Good manufacturing practices guide Manufacture of sterile drugs GUI-0119

GOOD MANUFACTURING PRACTICE

Contents. Contents (13) 1 Production (23)

Supplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.

Health Products and Food Branch Inspectorate

BFS IOA BFS Training 2018 Kunming Qualification and Validation of a BFS-Installation including CIP/SIP

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Sterilization - validation, qualification requirements. Sterilization - Overview

HISTORY AND MILESTONES

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Deficiencies found in Inspections and QP Responsibilities

Modular Turnkey Concept for Pharmaceutical Sterile Formulation Facilities

Webinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018

for IND and RDRC Regulated PET Compounding

Validation and Control of Porous Load Sterilisation

Guidance for Industry

EU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT

Purpose of GMP. The Underlying Principle. Why Media Fill? :Session 2: Qualification/validation of aseptic techniques dos and don ts 7/5/2014

Annex Draft Annex

Validation Master Plan

Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.

Good Manufacturing Practice for Advanced Therapy Medicinal Products

GUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEXES

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Validation Needs for Sterilization by Aseptic Filtration

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur

Unit 208 Assist with the manufacture and assembly of medicinal products

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM

ANNEX 5 MANUFACTURE OF IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS

Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM

Solutions for All Your Aseptic Parenteral Drug Formulation/Filling Needs. BUBBLE-FREE FILLING : A New Option in Prefilled Syringe Filling

GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS

Quality Risk Management

Prequalification of Medicines Programme

Environmental Control Requirements. Gordon Farquharson July 2017

Single-Use Final Fill: Benefits and Considerations

Risk classification guide for drug good manufacturing practices observations GUI-0023

Supersedes Division Name Revision No. 0 Export Division Page No. 1 of 9

GMP Inspection Deficiencies Review of Deficiencies Observed in 2013.

Managing Aseptic Interventions

CONTAINED ASEPTIC TRANSFER VALVES

Why change is inevitable in aseptic manufacturing?

Good manufacturing practices

Training Prospectus Public Course Dates

Aseptic Processing Current Issues & Trends

Validation Study on How to Avoid Microbial Contamination during Pharmaceutical Production

GMP Inspection Process. Types of GMP Inspection. Module 18 Slide 1 of 14 WHO - EDM

Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL:

Sun Pharmaceutical Industries Ltd. 12/17/15

A Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime

Public Health Service Food and Drug Administration Silver Spring, MD WARNING LETTER VIA UPS WL: December 17, 2015

GMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel

Drug, Device and Diagnostic Manufacturing

INSPECTOR S OBSERVATIONS AND WARNING LETTER

Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS

MANAGEMENT AND REQUALIFICATION OF STERILISATION PROCESSES

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

UNICEF Quality Assurance in the procurement of medicines

CONTAINED ASEPTIC TRANSFER VALVES

Extractable and Leachable Challenges From a generic injectable drug development perspective

The Parenteral Drug Association

GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET

Media Fill Evaluations in Cellular Therapy Product Manufacturing: Three Possible Approaches. Doug Padley Mayo Clinic

FlexAct BT (Bag Tester) Flexboy 2D November, 2015

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Introduction and Background

Prequalification of Medicines Programme

Cleaning validation of cleanrooms and preparation equipments

Contract Manufacturing Services for Pre-filled Syringes

Visible Particles: Regulatory and Compendial Requirements

SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION

Allergy Laboratories, Inc. 10/4/13

Risk based approaches for a sterility assurance application review: a microbiologist s perspective Dr. Yeissa Chabrier Roselló

Transcription:

Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1

Overview Guidance Best Practices Common Deficiencies Slide 2

Aseptic Process Validation = Process Simulation (Media Fill)? Date Insert on Master Slide Slide 3

A chain of linked activities Slide 4

Annex 1 Validation of aseptic processing should include a process simulation test using a nutrient medium (media fill) Imitate as closely as possible the routine aseptic manufacturing process Include all the critical subsequent manufacturing steps. Take into account various interventions known to occur during normal production as well as worst-case situations. Slide 5

Annex 1 Should be performed as initial validation with three consecutive satisfactory simulation tests per shift. Repeated at defined intervals and After any significant modification to the HVAC-system, equipment, process and number of shifts. Normally process simulation tests should be repeated twice a year per shift and process. The number of containers used for media fills should be sufficient to enable a valid evaluation. (Specific guidance given) Slide 6

Annex 1 For any run size, intermittent incidents of microbial contamination may be indicative of low-level contamination that should be investigated. Investigation of gross failures should include the potential impact on the sterility assurance of batches manufactured since the last successful media fill. Slide 7

Annex 1 No consolidated outline of sum total of validation of aseptic processing Various sections include additional validation requirements E.g. It should be demonstrated that air-flow patterns do not present a contamination risk, e.g. care should be taken to ensure that air flows do not distribute particles from a particle generating person, operation or machine to a zone of higher product risk. Slide 8

Guidance beyond process simulations Slide 9

PI 007 General Guidance Where filling takes place over extended periods, i.e. longer than 24 hours, the process simulation test should extend over the whole of the standard filling period. In order to prevent excessively high numbers of units being filled it is usually acceptable to just run the machine for a reasonable time, if the validity of the simulation is not diminished by this procedure. Inert gases will prevent the growth of aerobic microorganisms. Therefore for process simulations sterile filtered air should be used instead of inert gases, also for breaking vacuum General guidance on preparation of media Slide 10

PI 007 Product Specific Guidance Liquid Products Vial Products Sterile Products in Plastic Containers Ampoule Products Injectable Powder Products Suspension Products Freeze Dried (Lyophilised) Products Slide 11

PI 007 Product Specific Guidance Continued : Semi-Solid Products (e.g. sterile ointments) Clinical Trials Materials and Small Batch Size Products Biological and Biotechnology Products Sterile Bulk Pharmaceuticals Slide 12

PI 007 Process Simulation Test Conditions Process simulation test should represent a worst case situation and include all manipulations and interventions likely to be represented during a shift. Container size and line speed The fill volume of the containers should be sufficient to enable contact of all the container-closure seal surfaces when the container is inverted and also sufficient to allow the detection of microbial growth. Simulation tests should be performed on different days and hours during the week and not only at the beginning of a work day Slide 13

PI 007 Other Requirements Selection of Growth Medium Incubation Conditions Reading of the Test Test Frequency Interpretation of Data Slide 14

PI 007 Other Requirements Intervention Monitoring Essential to include the various interventions known to occur during normal production runs, e.g. : repair or replacement of needles / tubing, replacement of on-line filters, duration of stops on the line, filling and manipulation of stoppers etc. The process simulation test should last long enough to accommodate all possible interventions and a worst case scenario, which may include several unfavourable conditions which are occurring during routine processing. Slide 15

PI 007 Beyond Process Simulation Slide 16

PI 007 Beyond Process Simulation Beside process simulation, validation of aseptic manufacturing includes, but is not limited to other important factors: Staff Training Container/Closure Integrity Testing Container/Closure Sterilisation Equipment Cleaning and Sterilisation Slide 17

PI 007 Beyond Process Simulation Continued : Disinfection Filter Validation Vent Filters Equipment Maintenance and Testing Sterility Test Slide 18

PI 007 Beyond Process Simulation Staff Training Special emphasis as people are potentially one of the main sources of microorganisms in the environment Can t validate a person but can train them Training encompasses: basic microbiology, good manufacturing practice principles, hygiene (disinfection and sanitisation), aseptic connections, gowning procedures. Slide 19

PI 007 Beyond Process Simulation Container/Closure Integrity Testing Machine set-up is a critical factor Relate to validated settings Container/Closure Sterilisation Equipment Cleaning and Sterilisation Validation of sterilisation processes generally difficult Focuses primarily on steam sterilisation Slide 20

PI 007 Beyond Process Simulation Disinfection Sporicidal agents should be used wherever possible but particularly for spraying-in components and equipment in aseptic areas. The effectiveness of disinfectants and the minimum contact time on different surfaces should be validated. Filter Validation Validation should include microbiological challenges to simulate worst case production conditions Integrity test limits should be derived from the filter validation data Slide 21

PI 007 Beyond Process Simulation Vent Filters Less robust and more sensitive to pressure differentials during steam sterilisation In practice fail the integrity test more frequently than product filters Equipment Maintenance and Testing Aseptic holding and filling vessels should be subject to routine planned preventive maintenance All vessels should be subject to regular leak testing (pressure hold or vacuum hold) Slide 22

PI 007 Beyond Process Simulation Sterility Test The sterility test can provide useful information on the validation status of aseptic process However; Annex 1 The sterility test applied to the finished product should only be regarded as the last in a series of control measures by which sterility is assured. The test should be validated for the product(s) concerned Slide 23

Best Practice Sterility by Design? Proactive approach Process mapping All inputs with sterility impact Intervention mapping Updated based on real experience Risk assessment / management Slide 24

An approach Process mapping Risk assessment Identify, eliminate, reduce, mitigate, accept interventions Procedures Qualification of sanitisation and sterilisation Filter validation Smoke studies Training Monitoring Parts, components hold studies Gowning and personnel qualification Facility and equipment qualification Aseptic process simulations Environmental monitoring Sterility testing Evaluation of interventions Re-assessment Slide 25

Deficiencies Slide 26

Deficiencies Media Fills / General Not all units filled during media fills were incubated. SOP 123 did not indicate that vials were to be re-inverted after the seven day incubation period. There was no reconciliation of the quantity of units inspected against the quantity incubated. Consequently, units which could not be accounted for could not be presumed to be positive for growth. SOP 123 did not define the circumstances under which media fills could be aborted or invalidated. Slide 27

Deficiencies Media Fills / Process Simulation? Media fills did not proactively take into account the various interventions known to occur during normal production, as well as worst case situations. Interventions on filling nozzles were not simulated during media fills. Aseptic in process sampling for viscosity and water content was not simulated during media fills. Validation of aseptic processing was deficient in that media fills did not include a simulation of aseptic liquid manipulations relating to Component X, such as : Aseptic addition to the homogenisation vessel, Aseptic sampling from the vessel, Aseptic transfer from the homogenisation vessel to stainless steel buckets, Transfer of the filled buckets to the bulk vessel LAF, Aseptic addition to the bulk vessel. Slide 28

Deficiencies Media Fills / Personnel Qualification A list of personnel qualified through media fill participation, and the validity period of their qualification, was not maintained. The competence of individuals working in aseptic processing areas was not assessed through active participation in a media fill, prior to commencing routine work in the area. There was no requirement for individuals to be subject to routine requalification through active participation in media fills. There was no predefined minimum timeframe or predefined number and type of interventions which operators were required to perform, as part of qualification, during media fills. Slide 29

Deficiencies Media Fills / Interventions There was no system of active control of the simulation of interventions by operators during media fills and further to this for those media fill records which were reviewed, simulation of interventions were observed to be primarily performed by a mechanic. The process simulation study for Process X was deficient in that interventions A and B had not been performed by all relevant personnel as required by the media fill protocol. The set-up connections, 0.2µm filtration and the aseptic addition of solids had not been observed/recorded and subject to critical assessment during media fill studies. Slide 30

Deficiencies Media Fills / Failures In relation to the failure of Media Fill Batch 123, the assignable cause could not be substantiated in that: There was no record of filled units being damaged prior to incubation. The failure investigation report contained a statement with regard to an assignable cause for damage to units, which could not have been established retrospectively with regard to the detail in the associated batch manufacturing record. A microbiology report, indicating that the number of positive units found and the nature of bacteria isolated could not be conclusively linked to leaking/damaged units, was not addressed in the overall failure investigation. Slide 31

Questions Slide 32